Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.
Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.
The purpose of this study is to determine whether the transarterial supraselective
 embolization (TSE) is a technique as effective as transurethral resection of the prostate
 (TURP) for the treatment of lower urinary tract symptoms associated with benign prostatic
 hyperplasia (BPH).
Inclusion Criteria:

 -  Diagnosis of benign prostatic hyperplasia with moderate or severe obstructive lower
 urinary tract symptoms

 -  Refractory to medical treatment for at least 6 months

 -  Qmax (maximum urinary flow) less than 10 mL/second

 Exclusion Criteria:

 -  Patients not candidates for transurethral resection of the prostate (TURP)

 -  Advanced atherosclerosis and tortuosity of the iliac arteries

 -  No visualization of the prostatic artery CT angiography study

 -  Urethral stenosis, detrusor failure or neurogenic bladder

 -  Glomerular filtration < 30 mL/min

 -  Presence of malignant tumor

 -  History of allergy to iodinated contrast

 -  Patients with any other medical or social condition, deemed by the Investigator to be
 likely to interfere with a patient's ability to sign informed consent, cooperate and
 participate in the study, or interfere with the interpretation of the results